What's in a name? Memory NK cells for cancer immunotherapy.

IF 10.6 1区 医学 Q1 IMMUNOLOGY Journal for Immunotherapy of Cancer Pub Date : 2025-01-31 DOI:10.1136/jitc-2024-010850
Sean J Judge, Megan C Purl, William J Murphy, Robert J Canter
{"title":"What's in a name? Memory NK cells for cancer immunotherapy.","authors":"Sean J Judge, Megan C Purl, William J Murphy, Robert J Canter","doi":"10.1136/jitc-2024-010850","DOIUrl":null,"url":null,"abstract":"<p><p>The discovery that natural killer (NK) cells can retain features of \"memory\" from previous stimulation and pathogen exposure was a landmark advance highlighting one of many ways in which NK cells of the innate immune system resemble T cells of the adaptive immune system. This ability to \"remember\" prior stimulation to bring about enhanced protection of the host sparked significant excitement regarding potential therapeutic applications. Yet, how closely the features of naïve and memory NK cells recapitulate those of T cells remains unclear. Nonetheless, despite unresolved questions about the immunobiology of naïve and memory NK cells, the application of memory NK cells to the clinic for cancer and other indications has gathered steam to meet the unmet need for novel immunotherapies. Recent work from Arellano-Ballestero <i>et al</i> highlights this evolving field and the current state of the art with memory NK cells. Application of these cells to the clinic is progressing with promising results, but important questions remain about the essential molecular, phenotypic, and functional characteristics that define a memory NK cell.</p>","PeriodicalId":14820,"journal":{"name":"Journal for Immunotherapy of Cancer","volume":"13 1","pages":""},"PeriodicalIF":10.6000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792271/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal for Immunotherapy of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jitc-2024-010850","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The discovery that natural killer (NK) cells can retain features of "memory" from previous stimulation and pathogen exposure was a landmark advance highlighting one of many ways in which NK cells of the innate immune system resemble T cells of the adaptive immune system. This ability to "remember" prior stimulation to bring about enhanced protection of the host sparked significant excitement regarding potential therapeutic applications. Yet, how closely the features of naïve and memory NK cells recapitulate those of T cells remains unclear. Nonetheless, despite unresolved questions about the immunobiology of naïve and memory NK cells, the application of memory NK cells to the clinic for cancer and other indications has gathered steam to meet the unmet need for novel immunotherapies. Recent work from Arellano-Ballestero et al highlights this evolving field and the current state of the art with memory NK cells. Application of these cells to the clinic is progressing with promising results, but important questions remain about the essential molecular, phenotypic, and functional characteristics that define a memory NK cell.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
名字里有什么?记忆NK细胞用于癌症免疫治疗。
自然杀伤(NK)细胞可以保留先前刺激和病原体暴露的“记忆”特征,这一发现是一个里程碑式的进步,突出了先天免疫系统的NK细胞类似于适应性免疫系统的T细胞的许多方式之一。这种“记住”先前刺激的能力增强了对宿主的保护,引发了潜在治疗应用的重大兴奋。然而,naïve和记忆NK细胞的特征与T细胞的特征有多相似仍不清楚。尽管如此,尽管naïve和记忆NK细胞的免疫生物学仍存在未解决的问题,但将记忆NK细胞应用于临床治疗癌症和其他适应症已经聚集起来,以满足对新型免疫疗法的未满足需求。最近来自Arellano-Ballestero等人的工作突出了这一不断发展的领域和记忆NK细胞的当前状态。这些细胞在临床中的应用取得了可喜的结果,但是关于定义记忆NK细胞的基本分子、表型和功能特征的重要问题仍然存在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
17.70
自引率
4.60%
发文量
522
审稿时长
18 weeks
期刊介绍: The Journal for ImmunoTherapy of Cancer (JITC) is a peer-reviewed publication that promotes scientific exchange and deepens knowledge in the constantly evolving fields of tumor immunology and cancer immunotherapy. With an open access format, JITC encourages widespread access to its findings. The journal covers a wide range of topics, spanning from basic science to translational and clinical research. Key areas of interest include tumor-host interactions, the intricate tumor microenvironment, animal models, the identification of predictive and prognostic immune biomarkers, groundbreaking pharmaceutical and cellular therapies, innovative vaccines, combination immune-based treatments, and the study of immune-related toxicity.
期刊最新文献
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Bright side of the dark genome: antigens for next-gen cancer vaccines. Targeting the neuro-immune crosstalk in breast cancer brain metastases. Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1